TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02429674

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: TranS-C and IPT-A
Description: The goal of IPT-A is to decrease depressive symptoms by focusing on current interpersonal difficulties and helping the adolescent improve his or her relationships and interpersonal interactions. This is accomplished through psychoeducation about the adolescent's depression and its link to interpersonal relationships, review of the adolescent's significant relationships, identification of interpersonal problem areas on which to focus the treatment, development of interpersonal problem solving and communication skills, and role-playing. The sleep disturbances intervention will include several modules selected because they are successful treatments for insomnia, and/or may help promote adherence to some of the recommendations related to sleep.
Study: NCT00831285

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: food product
Description: food product given at one of six visits

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: food product
Description: food product given at one of six visits

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: food product
Description: food product given at one of six visits

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: food product
Description: food product given at one of six visits

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: food product
Description: food product given at one of six visits

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: food product
Description: food product given at one of six visits
Study: NCT00458887

Intervention type: PROCEDURE
Intervention: management of therapy complications
Description: Undergo hearing tests
Study: NCT02303522

Intervention type: OTHER
Intervention: Other: not applicable - observational study
Description: No intervention exists as this is a retrospective observational study
Study: NCT01945541

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Body Composition Monitoring
Description: Pre- and postoperative measurements of body composition (intracellular and extracellular water content)via bioimpedance spectroscopy
Study: NCT01789645

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conservative group
Description: The conservative group will received 3 treatment sessions of physical therapy based on neuromodulation of nociceptive processing of 30 minutes of duration, once per week.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical group
Description: The surgical group will receive the surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
Study: NCT00691405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol tartrate inhalation solution
Description: Arformoterol 5 mcg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol tartrate inhalation solution
Description: Arformoterol 15 mcg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol tartrate inhalation solution
Description: Arformoterol 25 mcg BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhalation solution BID
Study: NCT03193957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: Etanercept PFS and Autoinjector

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autoinjector
Description: Autoinjector
Study: NCT04043299

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 100% Oxygen
Description: High flow cylinder oxygen will be administered to women with fetal distress during labor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 21% oxygen
Description: High flow cylinder packaged medical air will be administered to women with fetal distress during labr
Study: NCT01342861

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Addition of protein (milky food in the breakfast)
Description: The main purpose of this study is to evaluate the efficacy of additional protein (adding milky food to the breakfast) in order to deliver an optimized protein and energy intake of 15.75 g and 559 Kcal, respectively.

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: Addition of protein (milky food in the breakfast)
Description: The main purpose of this study is to evaluate the efficacy of additional protein (adding milky food to the breakfast) in order to deliver an optimized protein and energy intake of 15.75 g and 559 Kcal, respectively.
Study: NCT00691405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol tartrate inhalation solution
Description: Arformoterol 15 mcg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol tartrate inhalation solution
Description: Arformoterol 25 mcg QD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arformoterol tartrate inhalation solution
Description: Arformoterol 50 mcg QD

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo inhalation solution QD
Study: NCT04364243

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digitally supported home exercises
Description: The training will comprise of 9 sessions (3 weekly) Each of the training sessions will last 20 minutes. This will result in a cumulative total intervention exercise time of 180 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digitally supported home exercises
Description: The training will comprise of 9 sessions (3 weekly) Each of the training sessions will last 20 minutes. This will result in a cumulative total intervention exercise time of 180 minutes.
Study: NCT02782689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kit Biflex
Description: Two-layer reusable compression system

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Profore
Description: Four-layer compression system
Study: NCT01877772

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Trephination
Description: For the bone trephination, the wire will be advanced into the insertion site through the cortex and into the metaphyseal bone of proximal humerus.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will undergo standard rotator cuff repair.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The control group will undergo standard rotator cuff repair.
Study: NCT00850603

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined
Description: 0.5 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined
Description: 0.1 mL, Subcutaneous

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined
Description: 0.05 mL, Intradermal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined
Description: 0.1 mL, Intradermal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined
Description: 0.15 mL, Intradermal
Study: NCT01849159

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Mesenchymal stem cells
Description: Intravenous infusion of MSC suspension, pre-conditioned under 1% oxygen, in the amount of 200 mln. cells per 400 mL of sodium chloride physiological solution

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Reference therapy: 400 mL of 0.9% NaCl solution
Study: NCT00715962

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral intervention
Description: Using social cognitive theory, participants in the walking program group will be encouraged to complete a brief diary about out of bed activities like sitting up for meals of walks to the bathroom. They will be provided with information regarding the importance of being out of bed a praise for any attempts. They will be asked to set out of bed time activity goals daily. The control group will have a diary to track visitors.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking Intervention
Description: Participants in the walking program will be assisted to walk twice a day by trained staff. Those in the control group will be visited twice a day for friendly visits only

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Friendly visits
Description: The control group will receive twice daily friendly visits and will be asked to complete a diary each day of the people who visit them in the hospital.
Study: NCT03938545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-1401 (Administered via subcutaneous injection)
Description: RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-1401 (Administered via subcutaneous injection)
Description: RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-1401 (Administered via subcutaneous injection)
Description: RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Administered via subcutaneous injection)
Description: Placebo
Study: NCT00816400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-575
Description: MEDI-575 as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-575
Description: MEDI-575 as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-575
Description: MEDI-575 as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-575
Description: MEDI-575 as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-575
Description: MEDI-575 as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-575
Description: MEDI-575 as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-575
Description: MEDI-575 as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-575
Description: MEDI-575 as an IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-575
Description: MEDI-575 as an IV infusion
Study: NCT03116737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzocaine Otic Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03468231

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Oral Sorafenib, 400mg, Bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Oral Sorafenib, 400mg, Bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAIC of FOLFOX
Description: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC of OXA
Description: administration of Oxaliplatin via the tumor feeding arteries
Study: NCT02511548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Financial incentive will be proposed to participant of the intervention arm
Study: NCT03237637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral propranolol
Description: oral propranolol 1-2mg/kg/day as crushed tablets in two divided doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral atenolol
Description: oral atenolol 0.5-1mg/kg/day as crushed tablets in a single dose
Study: NCT00819962

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine
Description: Local anesthetic

Intervention type: OTHER
Group type: OTHER
Intervention: TAP
Study: NCT03508037

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromodulation electroencephalographic signals and functional electrical stimulation based
Description: First, the subject performs twenty reaching movements without assistance with the damaged arm resting on a robot (ArmeoSpring), with the aim of finding the Contingent Negative Variation (CNV). Then, he or she executes five courses of twenty movements receiving functional electrical stimulation (FES), either at the moment in which he or she wishes to move (experimental group), or half a second before or after (control group).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromodulation electroencephalographic signals and functional electrical stimulation based
Description: First, the subject performs twenty reaching movements without assistance with the damaged arm resting on a robot (ArmeoSpring), with the aim of finding the Contingent Negative Variation (CNV). Then, he or she executes five courses of twenty movements receiving functional electrical stimulation (FES), either at the moment in which he or she wishes to move (experimental group), or half a second before or after (control group).
Study: NCT04843553

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Nicotinamide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Nicotinamide
Study: NCT00284817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-522
Description: Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 1 mg/kg for 51 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-522
Description: Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-522
Description: Administered as a 30-minute IV infusion; 6 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-522
Description: Administered as a 30-minute IV infusion; on Study Day 0 followed by weekly maintenance doses of 3mg/kg for 51 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-522
Description: The next cohort of patients will be treated after at least 3 of 4 patients treated in the previous cohort receive at least 3 weeks of treatment and experience no dose-limiting toxicity (DLT).
Study: NCT02856828

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIE
Description: digital image enhancement
Study: NCT01662726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irosustat
Description: Irosustat will be administered once daily in 40mg tablets. Treatment will start the day after the baseline FLT-PET and will be continued for a minimum of 2 weeks until the follow up FLT PET scan. For those patients who have consented to a repeat tumour biopsy, treatment will be extended to the day before the procedure. Study medication should be taken in the morning under fasting conditions with a glass of water, 30 minutes before breakfast.
Study: NCT02010008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Intervention
Description: An individual-level intervention that implements a motivational interviewing intervention led by a promotora
Study: NCT04566926

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284
Description: Participant will receive JNJ-64140284 formulation 1 or 2 under fasting or fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284
Description: Participant will receive JNJ-64140284 formulation 1 or 2 under fasting or fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284
Description: Participant will receive JNJ-64140284 formulation 1 or 2 under fasting or fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284
Description: Participant will receive JNJ-64140284 formulation 1 or 2 under fasting or fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participant will receive matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participant will receive matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participant will receive matching placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participant will receive matching placebo.
Study: NCT01773291

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture on GV26 and 12 Well points

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laser acupuncture
Description: laser acupuncture on GV26 and 12 Well points

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control
Description: sham laser acupuncture
Study: NCT03597074

Intervention type: DIAGNOSTIC_TEST
Intervention: color Doppler Ultrasound derived RI and semi-quantitative evaluation of intra-renal vascularization
Description: Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression

Intervention type: DIAGNOSTIC_TEST
Intervention: color Doppler Ultrasound derived RI and semi-quantitative evaluation of intra-renal vascularization
Description: Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression

Intervention type: DIAGNOSTIC_TEST
Intervention: color Doppler Ultrasound derived RI and semi-quantitative evaluation of intra-renal vascularization
Description: Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
Study: NCT00901186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RFB002
Description: 0.5 mg

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser photocoagulation
Study: NCT02943486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dac-MSCs
Description: Cell-free therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MSCs
Description: Cell-based therapy
Study: NCT04536558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine plus fosaprepitant-based triple regimen
Description: olanzapine 5mg p.o. on day 1-day 5, fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. Patients received ondansetron hydrochloride(8mg, i.v. day 1-day 3) and dexamethasone(6mg, oral, day 1-day 5) at the same time, before undergoing chemotherapy.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo plus fosaprepitant-based triple regimen
Description: placebo p.o. on day 1-day 5, fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. Patients received ondansetron hydrochloride(8mg, i.v. day 1-day 3) and dexamethasone(6mg, oral, day 1-day 5) at the same time, before undergoing chemotherapy.
Study: NCT01134185

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prucalopride
Description: single oral dose of 2 mg prucalopride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prucalopride
Description: single oral dose of 2 mg prucalopride

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prucalopride
Description: single dose of 2 mg prucalopride
Study: NCT02242773

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-Parametric MRI
Description: Multi-Parametric MRI

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-Guided Biopsy
Description: MRI-Guided Biopsy
Study: NCT02943486

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fitostimoline
Description: Triticum vulgare

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fitostimoline
Description: Triticum vulgare

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fitostimoline
Description: Triticum vulgare
Study: NCT01201317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2423
Description: 20 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2423
Description: 150 mg tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00679237

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: smoking cessation
Description: NRT and varenicline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betablocker, diuretics, ACEI, ARB,
Description: blood pressure control according to ESC guidelines

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: statins, ezetimibe
Description: Cholesterol reduction according to ESC guidelines

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: training
Description: daily walking

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: influenza vaccine
Description: vaccine (FLuarix, Influvac etc)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin, glimepiride, insulin
Description: s.glucose control according to ESC guidelines

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: weight reduction
Description: diet tips
Study: NCT00385216

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Nicotine nasal spray 3mg x 1 before surgery

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray 0mg x 1 before surgery
Study: NCT02839759

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TELLYHealth
Description: Educational videos and questions.
Study: NCT04420715

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training on coronary angiography using 3D coronary artery simulator
Description: Participants will have a test of coronary arteriography before and after training, compare the scores to analysis if the simulator training is effective.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training on coronary angiography using 3D coronary artery simulator
Description: Participants will have a test of coronary arteriography before and after training, compare the scores to analysis if the simulator training is effective.
Study: NCT02377115

Intervention type: OTHER
Group type: OTHER
Intervention: Tablet computer application
Description: Preoperatively, all study participants (entire cohort) will perform in the self-administered tablet computer-based tool to assess the risk of developing POD.
Study: NCT03720054

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MapTrek
Description: Our objective is to report activity levels in our virtual environment to veterans, thereby encouraging them first, to walk more every day, and second, to maintain these new increased levels of physical activity. MapTrek will also motivate veterans to accumulate less sedentary time.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit
Description: Fitbit Only
Study: NCT02774031

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aisys with Et control

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aisys conventional

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow-i with ACG

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flow-i conventional